Skip to main content

Table 3 Clinical and biochemical characteristics in subjects without diabetes, or obesity or metabolic syndrome and in statin non users according to the presence or absence of NAFLD

From: NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease

  Subjects w/o diabetes Subjects w/o obesity^ Subjects w/o MetS Subjects w/o statin use
  Nafld (144) no-Nafld (43) Nafld (85) no-Nafld (39) Nafld (73) no-Nafld (41) Nafld (139) no-Nafld (28)
Age (yrs) 52,1 ± 12,7 54,4 ± 14 55,0 ± 13,0 55,0 ± 14,7 50,1 ± 13,1 54,7 ± 13,0 50,8 ± 11,8 53,0 ± 15,9
Male gender (%) 33,3 34,9 23,8 34,2 31,8 30,6 36,0 39,3
BMI 30,9 ± 5,6 26,9 ± 3,7 *** 26,6 ± 2,3 25,2 ± 2,0*** 29,5 ± 5,7 26,5 ± 3,5** 31,0 ± 5,8 27,2 ± 3,9***
Urinary 8-iso-PGF2α (pg/mg creatinine) 703,4 ± 117,9 634,1 ± 106,7*** 626,6 ± 81,5 583,6 ± 102,7* 672,1 ± 123,0 619,3 ± 95,1* 711,6 ± 133 627,5 ± 147,9**
sNOX2-dp (pg/ml) 56,4 ± 13,8 49,9 ± 8,9*** 49,4 ± 12,9 45,8 ± 8,9 54,0 ± 13,3 48,4 ± 8,3* 57,5 ± 14,1 47,5 ± 10,7***
Adiponectin (ng/ml) 8,5 (5,5/12) 13,5 (7,5/15)*** 12,5 (10,5/14) 13,5 (12,5/14,5)** 10,5 (6,2/13,6) 13,0 (6,5/14)* 7,5 (5/11,5) 13,5 (6,8/15)***
Cytokeratin-18 (mIU/ml) 174,5 (136/189) 130,0 (125/175)** 149,0 (125/179) 126,0 (110/165)* 161,5 (125/180 165,0 (125/178) 179,0 (145/190) 140,0 (125/179)**
ALT (IU/L) 26 (20/40) 20 (15/27)*** 34 (23/42) 15 (13/24)*** 26 (19/27) 18 (14/27)** 27 (20/40) 18 (14/27)***
GGT (IU/L) 25 (17/40)* 20 (14/28) 30 (20/52) 21 (16/23)** 23 (16/10) 21 (18/36) 25 (17/44)* 21 (13/30)
HOMA_IR 2,9 (2,1/4,5) 1,8 (1,2/2,1)*** 2,8 (1,8/4,3) 2,0 (1,6/3,2) 2,6 (1,7/3,4) 1,8 (1,5/2,1)* 3,1 (2,2/5,5) 1,8 (1,1/2,1)***
MetS§ (%) 57,0 12,5*** 51,8 19,4*** 0 0 57,8 16,0***
High Fasting Glucose§ (%) 32,9 19,5 44,0 30,6 15,2 13,9 41,3 23,1
High Triglycerides§ (%) 44,8 11,9*** 39,3 16,2* 7,6 13,9 40,9 11,1**
High Waist Circumference§ (%) 78,2 43,9*** 55,4 27,0** 59,1 38,9 80 46,2***
Low C-HDL§ (%) 35,7 16,7* 31,0 21,6 6,1 13,9 37,2 14,8*
High Blood Pressure§ (%) 79,0 74,4 81,0 73,7 69,7 75,0 80,3 75,0
Diabetes (%) 0 0 21,4 15,8 7,6 2,8 20,1 7,1
Statin use (%) 22,9 39,5* 31,0 47,4 13,6 41,7** 0 0
  1. *p< ,05; **p< ,01; ***p< ,001; §According to ATPIII modified criteria (Ref. 30); ^BMI > 30.0.